Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Ernexa Therapeutics' Income from Continuing Operations rose 9533.9% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.4 million, marking a year-over-year increase of 5913.92%. This contributed to the annual value of -$44.6 million for FY2024, which is 10564.43% down from last year.
  • According to the latest figures from Q3 2025, Ernexa Therapeutics' Income from Continuing Operations is -$1.2 million, which was up 9533.9% from -$3.1 million recorded in Q2 2025.
  • Ernexa Therapeutics' 5-year Income from Continuing Operations high stood at -$1.2 million for Q3 2025, and its period low was -$86.0 million during Q3 2021.
  • For the 5-year period, Ernexa Therapeutics' Income from Continuing Operations averaged around -$12.2 million, with its median value being -$5.8 million (2024).
  • Per our database at Business Quant, Ernexa Therapeutics' Income from Continuing Operations tumbled by 570594.19% in 2021 and then soared by 9533.9% in 2025.
  • Over the past 5 years, Ernexa Therapeutics' Income from Continuing Operations (Quarter) stood at -$86.0 million in 2021, then surged by 94.78% to -$4.5 million in 2022, then tumbled by 37.07% to -$6.2 million in 2023, then grew by 6.08% to -$5.8 million in 2024, then soared by 78.54% to -$1.2 million in 2025.
  • Its Income from Continuing Operations was -$1.2 million in Q3 2025, compared to -$3.1 million in Q2 2025 and -$8.2 million in Q1 2025.